Eli Lilly (LLY) Financial Analysis & Valuation | Quarter Chart
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a... more
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Ba... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $1.08T | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | David A. Ricks |
| IPO Date | 1972-06-01 | CAGR | 7.77% |
| Employees | 50,000 | Website | www.lilly.com |
| Div. Yield | 0.59% | Payout Ratio | 22% |
| Buy Back Yield | 0.61% | Total Yield | 1.2% |
LLY chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $1081.88B | P/E | 36.29 | Forward P/E | 24.01 | PEG | 1.47 |
| P/S | 13.47 | P/B | 30 | P/CF | 36.15 | P/FCF | 53.5 |
| Sales | $79.67B | Sales 1Y | 49.58% | Sales 3Y | 169.91% | Sales 5Y | 198.08% |
| EPS | $31.49 | EPS 1Y | 94.77% | EPS 3Y | 330.01% | EPS 5Y | 364.9% |
| Sales QoQ | 16.04% | EPS QoQ | -3.87% | Sales QoQ Avg | 10.35% | EPS QoQ Avg | 6.41% |
| Gross Margin | 84.01% | Operating Margin | 43.92% | Profit Margin | 33.53% | ROCE | 37.01% |
| ROA | 19% | ROE | 93% | Altman Z Score | 7.71 | Piotroski Score | 8 |
| Current Ratio | 1.35 | Quick Ratio | 1 | Cash Ratio | 0.19 | Op. CF Ratio | 0.22 |
| Debt/Equity | 1.62 | Debt/Assets | 0.39 | Lt Debt/Equity | 1.41 | Lt Debt/Cap. | 0.59 |
| Intrst Cov. | 35.72 | Inventory Turnover | 0.76 | Asset Turnover | 0.56 | Receivables Turnover | 3.39 |
| Enterprise Value | $1081.88B | P/E Ratio | 36.29 |
| Forward P/E | 24.01 | PEG Ratio | 1.47 |
| P/S Ratio | 13.47 | P/B Ratio | 30 |
| P/CF Ratio | 36.15 | P/FCF Ratio | 53.5 |
| EPS | $31.49 | EPS Growth 1Y | 94.77% |
| EPS Growth 3Y | 330.01% | EPS Growth 5Y | 364.9% |
| Revenue Growth 1Y | 49.58% | Gross Margin | 84.01% |
| Operating Margin | 43.92% | Profit Margin | 33.53% |
| ROE | 93% | ROA | 19% |
| ROCE | 37.01% | Current Ratio | 1.35 |
| Quick Ratio | 1 | Cash Ratio | 0.19 |
| Debt/Equity | 1.62 | Interest Coverage | 35.72 |
| Altman Z Score | 7.71 | Piotroski Score | 8 |
Eli Lilly (LLY) valuation & financials
Eli Lilly (LLY) has a market capitalization of $1.08T and trades at a price-to-earnings ratio of 36.3. It operates in the Healthcare sector (Drug Manufacturers - General).
Eli Lilly's revenue grew +49.6% over the last year.
Eli Lilly's next earnings report is scheduled for October 29, 2026 before market open (provider scheduled date); analysts estimate EPS of $9.92. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW) · Novartis (NVS)